Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13261436 | 1.00 | GBA1 (0.41) | GBA1GAATP53PIK3CDALDH1A1 | |
| SCHEMBL13261425 | 1.00 | GBA1 (0.41) | GBA1GAATP53PIK3CDALDH1A1 | |
| SCHEMBL13223796 | 0.81 | PIK3CD (0.45) | PIK3CDNAAA | |
| SCHEMBL13223797 | 0.81 | PIK3CD (0.45) | PIK3CDNAAA | |
| SCHEMBL10337314 | 0.80 | PIK3CD (0.37) | PIK3CDFAAHNAAA | |
| SCHEMBL16327299 | 0.80 | PIK3CD (0.37) | PIK3CDFAAHNAAA | |
| SCHEMBL16327334 | 0.80 | PIK3CD (0.37) | PIK3CDFAAHNAAA | |
| SCHEMBL15013873 | 0.79 | — | — | |
| SCHEMBL2631378 | 0.79 | — | — | |
| SCHEMBL15134202 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | disclosed |
| CN-107021932-A | Process for the preparation of 5-L-aminomethyl-3-aryl-2-oxazolidone | 欧美嘉股份有限公司 | 2017-08-08 | — | — | CN | disclosed |
| US-8222200-B2 | Organic compounds | GIVAUDAN SA (CH) | 2012-07-17 | — | — | US | disclosed |
| EP-1613587-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-12-30 | — | — | EP | disclosed |
| US-20060270588-A1 | Organic compounds | GIVAUDAN SA (CH) | 2006-11-30 | — | — | US | disclosed |
| EP-1613587-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089880-A2 | CARBAMATES USEFUL AS FRAGANCES | GIVAUDAN SA (CH) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270588-A1 | Organic compounds | VDAC1, OR51E2, VDAC2 | GBA1 4193/4885GAA 2452/4885TP53 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.